

# Alexy Inciarte

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8089078/alexey-inciar-te-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38 papers	644 citations	10 h-index	25 g-index
46 ext. papers	1,125 ext. citations	4.9 avg, IF	3.56 L-index

#	Paper	IF	Citations
38	Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. <i>Clinical Microbiology and Infection</i> , <b>2021</b> , 27, 83-88	9.5	280
37	Smell and Taste Dysfunction in COVID-19 Is Associated With Younger Age in Ambulatory Settings: A Multicenter Cross-Sectional Study. <i>Journal of Investigational Allergology and Clinical Immunology</i> , <b>2020</b> , 30, 346-357	2.3	51
36	Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study. <i>Aids</i> , <b>2020</b> , 34, 1775-1780	3.5	47
35	Overview of SARS-CoV-2 infection in adults living with HIV. <i>Lancet HIV</i> , <b>2021</b> , 8, e294-e305	7.8	46
34	Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 1965-1971	5.1	32
33	Association of microbial translocation biomarkers with clinical outcome in controllers HIV-infected patients. <i>Aids</i> , <b>2015</b> , 29, 675-81	3.5	29
32	HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses. <i>Journal of Virology</i> , <b>2015</b> , 89, 9189-99	6.6	28
31	Impact of low serum calcium at hospital admission on SARS-CoV-2 infection outcome. <i>International Journal of Infectious Diseases</i> , <b>2021</b> , 104, 164-168	10.5	19
30	Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. <i>Thorax</i> , <b>2021</b> , 76, 920-929	7.3	12
29	Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. <i>Lancet HIV</i> , <b>2021</b> , 8, e701-e710	7.8	10
28	A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 1987-93	5.1	8
27	A case of Japanese encephalitis in a 20 year-old Spanish sportsman, February 2013. <i>Eurosurveillance</i> , <b>2013</b> , 18, 20573	19.8	8
26	A 24-week pilot study of dual maintenance therapy with raltegravir and lamivudine. <i>Aids</i> , <b>2019</b> , 33, 1891-1896	3.5	7
25	Cytomegalovirus infection in HIV-infected patients in the era of combination antiretroviral therapy. <i>BMC Infectious Diseases</i> , <b>2019</b> , 19, 1030	4	7
24	A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 1982-6	5.1	6
23	Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 2857-2861	5.1	6
22	Factors Associated with Hospitalization among Emergency Department Patients Referred for Quick Investigation of Iron-Deficiency Anemia. <i>Journal of Emergency Medicine</i> , <b>2016</b> , 50, 394-402.e1	1.5	5

21	High circulating SDF-1 and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patients. <i>EBioMedicine</i> , <b>2020</b> , 62, 103077	8.8	5
20	Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection. <i>Revista Espanola De Quimioterapia</i> , <b>2021</b> , 34, 238-244	1.6	5
19	C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19.. <i>Scientific Reports</i> , <b>2022</b> , 12, 5250	4.9	5
18	Experience with the use of siltuximab in patients with SARS-CoV-2 infection. <i>Revista Espanola De Quimioterapia</i> , <b>2021</b> , 34, 337-341	1.6	4
17	Predictive Factors for HIV Seroconversion Among Individuals Attending a Specialized Center After an HIV Risk Exposure: A Case-Control Study. <i>AIDS Research and Human Retroviruses</i> , <b>2016</b> , 32, 1016-1021	1.6	4
16	Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 3296-3302	5.1	4
15	Post-exposure prophylaxis for HIV infection in sexual assault victims. <i>HIV Medicine</i> , <b>2020</b> , 21, 43-52	2.7	3
14	IL7RA polymorphisms are not associated with AIDS progression. <i>European Journal of Clinical Investigation</i> , <b>2017</b> , 47, 719-727	4.6	2
13	About "Executive summary of the GeSIDA consensus document on control and monitoring of HIV-infected patients". <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , <b>2020</b> , 38, 299-300	0.9	2
12	Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort Study. <i>Infectious Diseases and Therapy</i> , <b>2021</b> , 10, 1253-1266	6.2	2
11	Gustatory and olfactory dysfunctions in hospitalised patients with COVID-19 pneumonia: a prospective study. <i>BMJ Open</i> , <b>2021</b> , 11, e040775	3	2
10	Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data. <i>Infectious Diseases and Therapy</i> , <b>2021</b> , 1	6.2	1
9	Effective Treatment of Lymphogranuloma venereum Proctitis With Azithromycin. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, 614-620	11.6	1
8	Increasing emergency department admissions for chemsex-related intoxications in Barcelona, Spain, among people living with HIV: an observational study from 2018 to 2020.. <i>BMC Public Health</i> , <b>2022</b> , 22, 346	4.1	1
7	Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57).. <i>Open Forum Infectious Diseases</i> , <b>2022</b> , 9, ofab595	1	0
6	Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection. <i>Trials</i> , <b>2021</b> , 22, 851	2.8	0
5	Network meta-analysis of post-exposure prophylaxis randomized clinical trials. <i>HIV Medicine</i> , <b>2021</b> , 22, 218-224	2.7	0
4	Factors associated with the use and composition of two-drug regimens in a large single-centre HIV cohort. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 2988-2992	5.1	0

3	Vulnerability Conditions in a Cohort of Men Who Have Sex with Men Who Engage in Chemsex in Barcelona City: a Cross-Sectional Study. <i>Sexuality Research and Social Policy</i> ,1	2.1	o
2	Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon $\beta$ 2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 767370	8.4	o
1	Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patients.. <i>Infection</i> , <b>2022</b> , 1	5.8	o